A global biopharma company, inspired by the needs of people living with severe diseases.
At UCB, we are consistently delivering on our commitment to improve the lives of people living with severe neurological and immunological conditions. And thanks to our focused, innovative and trusted solutions, our business is strong.
Our people have lived our purpose each day since 1928, making critical investments in biopharmaceutical research and leading innovations that strive to achieve a meaningful impact on the lives of those we serve.
UCB’s ambition is to transform the lives of people living with severe diseases, allowing them to live the best life that they can – as free as possible from the challenges and uncertainty of disease. That commitment comes to life in our research and development activities across neurology, immunology and other areas where our expertise, innovation and ambition align with unmet needs.
1928
Served areaWorldwide
Headcount8,600
HeadquartersAllée de la Recherche 60, 1070 Bruxelles, Bruxelles-Capitale – Belgium
194,505,658
IPOJan. 1, 2000
Stock exchange(s)Euronext Brussels